Hepatocellular Carcinoma Clinical Trial
Official title:
Irradiation Stent Placement Plus Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Multicenter Randomized Study
The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with advanced HCC accompanied by portal vein tumor thrombosis. Patients will be randomized to receive either portal irradiation stent placement plus TACE(Arm A) or Sorafenib plus TACE (Arm B).
The prognosis of HCC with portal vein tumor thrombosis (PVTT) is dismal, with a median
survival of 2.7-4.0 months compared to that of 10.0-24.0 months without PVTT. Therefore, the
presence of PVTT is regarded as a hallmark of advanced HCC and has a high incidence of
39-63%.
PVTT can accompany intrahepatic tumor spread, liver function deterioration, and portal vein
hypertension, and can lead to intractable ascites, variceal rupture, hepatic encephalopathy
and/or death. As recommended by the Barcelona Clinic Liver Cancer (BCLC) group, the current
standard treatment of HCC with PVTT is sorafenib only. However, sorafenib monotherapy does
not achieve satisfactory outcomes, yielding a median survival time of 5.6 to 8.1 months. To
improve the prognosis, transarterial chemoembolization (TACE), surgical resection,
radiotherapy, ablations, and radioembolization have been applied to treat patients with HCC
and PVTT, with improved outcomes reported.
Portal vein stent placement is regarded as a safe and effective technique in relieving portal
hypertension, extending treatment options, and prolonging survival in patients with HCC and
PVTT. However, the reported stent patency period of 3.7 months and survival time of 2.2 to
6.1 months may not be interpreted as satisfactory outcomes, mainly limited by rapid tumor
infiltration and/or subsequent thrombosis formation.
An irradiation stent has been developed and confirmed to be safe and effective in treating
unresectable esophageal cancer. A modified irradiation stent designed for biliary tract
obstruction was subsequently developed and resulted in significantly improved outcomes in a
single-institute randomized, controlled study of patients with malignant biliary obstruction.
This study aims to demonstrate that overall survival on portal irradiation stent placement
plus TACE is superior to overall survival on sorafenib plus TACE in patients with advanced
hepatocellular carcinoma accompanied by portal vein tumor thrombosis. Secondary Objectives
includes 1. To compare time to progression between both treatment groups; 2. To compare
hepatic function between both treatment groups; 3.To compare the disease control rate of the
intrahepatic lesions between both treatment groups; 4.To evaluate and compare the safety and
tolerability of both treatment groups; 5. To compare portal patency both treatment groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |